



28 October 2020

ASX Announcement



PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

Taiwan FDA approval for PolyNovo

PolyNovo is excited to announce the approval of NovoSorb BTM by the Taiwan FDA for sale in Taiwan.

PolyNovo said it has also contracted with Evermed, a Taiwan based distributor to sell BTM.

Managing Director, Paul Brennan said, *"This is an exciting development for PolyNovo. Taiwan has an advanced health system and has a population of circa 23 million concentrated in three regions. The dermal matrix market in Taiwan has good potential for us in reconstructive surgery, trauma and burns."*

Mr. Brennan went on to say that *"Evermed is a very good partner and has 20 sales staff focused on medical devices. The company has well established relationships with hospitals and key opinion leaders throughout Taiwan."*

In order to start selling, Evermed needs to lodge reimbursement data with the health authority, typically a three-month process, to achieve billing codes for use by the hospitals. First sales are anticipated circa March 2021.

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

Further information:

Paul Brennan
Managing Director
Mobile: + 61 427 662 317

About NovoSorb®

NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile. NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn.

About Evamed

Evermed is a private company with offices in the three major regions of Taiwan. www.evermed.com.tw